Procept BioRobotics announces 5-year results from WATER II Study

PROCEPT BioRobotics Corporation announced that 5-year results from the WATER II Study demonstrate that Aquablation therapy, a minimally invasive, robotic, surgical treatment for benign prostatic hyperplasia, safely and effectively provides durable symptom relief and preserves sexual function out to five years for men with large prostates. The study, published in this month’s Journal of Urology, demonstrated that patients continued to experience significant and long-term improvement in their symptoms and quality of life. The WATER II Study is the first FDA, prospective multicenter study successfully completed for larger prostates. The 5-year results maintained excellent clinical outcomes including a significant reduction in IPSS, increase in peak urinary flow rate and improvement in quality of life. "Aquablation therapy now has 5-year results from two pivotal studies that demonstrate the reproducibility of Aquablation therapy to deliver significant symptom relief while preserving sexual function no matter the size of the patient’s prostate,"said Sham Shiblaq, EVP and Chief Commercial Officer of PROCEPT BioRobotics. "These results are further validated by the large and growing number of hospitals and surgeons that have adopted Aquablation as their new standard of care for the treatment of BPH."